Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Impact of Fludarabine Dosage on Outcomes in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy: A Retrospective Study on Behalf of the Ctiwp of the EBMT

Blood (2024) 144 (Supplement 1): 3456.

https://doi.org/10.1182/blood-2024-211010

Published: 2024

Journal Articles

The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party

Laura G.M. Daenen, Lotte Van Der Wagen, Edouard F. Bonneville, Lucia Lopez Corral, Laimonas Griskevicius, Martin Bornhäuser, Yves Beguin, Maija Itala-Remes, Jorinde D. Hoogenboom, Liesbeth C. de Wreede, Florent Malard, Christian Chabannon, Francesco Dazzi, Annalisa Ruggeri, Jurgen Kuball

Blood (2024) 144 (Supplement 1): 4907.

https://doi.org/10.1182/blood-2024-201358

Published: 2024

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft- Versus -Host Disease : Results from Early Access Program in Europe

Blood (2024) 144 (Supplement 1): 4903.

https://doi.org/10.1182/blood-2024-201251

Published: 2024

Journal Articles

Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)

Blood (2024) 144 (Supplement 1): 4765.

https://doi.org/10.1182/blood-2024-206867

Published: 2024

Journal Articles

Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS

Blood (2024) 144 (16): 1747–1751.

https://doi.org/10.1182/blood.2024024351

Published: 2024

Includes: Supplemental data

Journal Articles

HLA Class I Mismatches Reduce Survival after HCT in the Ptcy Era: A Study By the EBMT Cellular Therapy and Immunobiology Working Party

Blood (2023) 142 (Supplement 1): 2178.

https://doi.org/10.1182/blood-2023-185945

Published: 2023

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Blood (2023) 142 (Supplement 1): 3553.

https://doi.org/10.1182/blood-2023-185751

Published: 2023

Journal Articles

Potential future direction of measurable residual disease evaluation in multiple myeloma

Mohamad Mohty, Hervé Avet-Loiseau, Florent Malard, Jean-Luc Harousseau

Blood (2023) 142 (18): 1509–1517.

https://doi.org/10.1182/blood.2023020284

Published: 2023

Includes: Supplemental data

Journal Articles

A Multicentre, Randomized, Double-Blinded, Phase 2b Study Evaluating the Efficacy and Safety of MaaT033, an Oral, Pooled Microbiome Ecosystem Therapy in Patients Undergoing Allogenic Hematopoietic Cell Transplantation to Improve Overall Survival: The Phoebus Trial

Florent Malard, Myriam Labopin, Ernst Holler, Joël Doré, Emilie Plantamura, Mohamad Mohty

Blood (2023) 142 (Supplement 1): 4947.

https://doi.org/10.1182/blood-2023-185639

Published: 2023

Journal Articles

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): Update of the IFM Study from the Descar-T Registry

Blood (2023) 142 (Supplement 1): 2139.

https://doi.org/10.1182/blood-2023-188655

Published: 2023

Journal Articles

IL-22, a new beacon in gastrointestinal aGVHD

Mohamad Mohty, Florent Malard

Blood (2023) 141 (12): 1369–1370.

https://doi.org/10.1182/blood.2022018934

Published: 2023

Journal Articles

MO-TRANS: A Phase 2b Placebo-Controlled Study of Mocravimod As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplant

Marcos de Lima, Florent Malard, Eduardo Olavarria, Estefanía Pérez López, Michael Medinger, Elisabeth Kueenburg, Malika Souquieres, Julien Cachat, Christos Stylianou, Patrice Chevallier

Blood (2022) 140 (Supplement 1): 12936–12937.

https://doi.org/10.1182/blood-2022-159785

Published: 2022

Journal Articles

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in France

Blood (2022) 140 (Supplement 1): 276–278.

https://doi.org/10.1182/blood-2022-163340

Published: 2022

Journal Articles

Restoration of Gut Microbiota Diversity with Oral Pooled Fecal Microbiotherapy in Acute Myeloid Leukemia Patients after Intensive Chemotherapy: The Phase 1b Cimon Trial

Florent Malard, Sylvain Thepot, Thomas Cluzeau, Martin Carre, Delphine Lebon, Cyrielle Gasc, Juliette Jouve, Benoit Levast, Emilie Plantamura, Emmanuel Prestat, Antoine Sabourin, Joel Doré, Mohamad Mohty, Christian Recher

Blood (2022) 140 (Supplement 1): 6215–6217.

https://doi.org/10.1182/blood-2022-165938

Published: 2022

Journal Articles

Activity of Ex Vivo Graft and DLI Engineering within the Last Decade Increases, a Survey from the EBMT Cellular Therapy & Immunobiology Working Party

Moniek de Witte, Jorinde Hoogenboom, Jarl Mooyaart, Christian Chabannon, Florent Malard, Annalisa Ruggeri, Jurgen Kuball

Blood (2022) 140 (Supplement 1): 4741–4742.

https://doi.org/10.1182/blood-2022-157422

Published: 2022

Journal Articles

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry

Blood (2022) 140 (Supplement 1): 4668–4670.

https://doi.org/10.1182/blood-2022-162682

Published: 2022

Journal Articles

Reduced Post-Transplant Cyclophosphamide Dose Associated with Antithymocyte Globulin in Peripheral Blood Stem Cell Haploidentical Transplantation

Remy Dulery, Florent Malard, Eolia Brissot, Anne Banet, Simona Sestili, Ramdane Belhocine, Martina Calabrò, Zoé Van De Wyngaert, Agnès Bonnin, Tounes Ledraa, Ollivier Legrand, Myriam Labopin, Elodie Capderou, Ariel Cohen, Stéphane Ederhy, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 10517–10518.

https://doi.org/10.1182/blood-2022-165104

Published: 2022

Journal Articles

Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program

Blood (2021) 138 (Supplement 1): 262.

https://doi.org/10.1182/blood-2021-147709

Published: 2021

Journal Articles

Sequential Conditioning Regimen with Thiotepa in Allogeneic Hematopoietic Cell Transplantation for the Treatment of Refractory Myeloid Malignancies

Blood (2021) 138 (Supplement 1): 1796.

https://doi.org/10.1182/blood-2021-150498

Published: 2021

Journal Articles

Let’s reconstitute microbiota diversity

Florent Malard, Mohamad Mohty

Blood (2021) 137 (11): 1442–1444.

https://doi.org/10.1182/blood.2020009963

Published: 2021

NARROW

Impact of Fludarabine Dosage on Outcomes in Large B-Cell Lymphoma Patients Treated with CAR T-Cell Therapy: A Retrospective Study on Behalf of the Ctiwp of the EBMT

The Use of MSCs in Steroid-Refractory Acute GvHD in Europe: A Survey from the EBMT Cellular Therapy & Immunobiology Working Party

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft- Versus -Host Disease : Results from Early Access Program in Europe

Prognostic Value of Positron Emission Tomography/Computed Tomography in Multiple Myeloma Patients Treated with Ide-Cel CAR-T Cell Therapy: Preliminary Results of a Real-World IFM Study from the Descar-T Registry (CAR MY PET)

Directionality of HLA-DP permissive mismatches improves risk prediction in HCT for acute leukemia and MDS

HLA Class I Mismatches Reduce Survival after HCT in the Ptcy Era: A Study By the EBMT Cellular Therapy and Immunobiology Working Party

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease : Results from Early Access Program in Europe

Potential future direction of measurable residual disease evaluation in multiple myeloma

A Multicentre, Randomized, Double-Blinded, Phase 2b Study Evaluating the Efficacy and Safety of MaaT033, an Oral, Pooled Microbiome Ecosystem Therapy in Patients Undergoing Allogenic Hematopoietic Cell Transplantation to Improve Overall Survival: The Phoebus Trial

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): Update of the IFM Study from the Descar-T Registry

IL-22, a new beacon in gastrointestinal aGVHD

MO-TRANS: A Phase 2b Placebo-Controlled Study of Mocravimod As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplant

Pooled Fecal Allogenic Microbiotherapy for Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Early Access Program in France

Restoration of Gut Microbiota Diversity with Oral Pooled Fecal Microbiotherapy in Acute Myeloid Leukemia Patients after Intensive Chemotherapy: The Phase 1b Cimon Trial

Activity of Ex Vivo Graft and DLI Engineering within the Last Decade Increases, a Survey from the EBMT Cellular Therapy & Immunobiology Working Party

French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): An IFM Study from the Descar-T Registry

Reduced Post-Transplant Cyclophosphamide Dose Associated with Antithymocyte Globulin in Peripheral Blood Stem Cell Haploidentical Transplantation

Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program

Sequential Conditioning Regimen with Thiotepa in Allogeneic Hematopoietic Cell Transplantation for the Treatment of Refractory Myeloid Malignancies

Let’s reconstitute microbiota diversity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only